The instruction for medical use
of Tserakson® medicine
the Trade name
the International unlicensed
name Tsitikolin Lekarstvennaya a form
Solution for intravenous and intramuscular administration of 500 mg / 4 ml, 1000 mg / 4 ml
One ampoule (4 ml) contains Structure:
active agent – tsitikolin sodium of 522.5 mg (500 mg
of a tsitikolin are equivalent) or 1045.0 mg (1000 mg of a tsitikolin are equivalent),
excipients: acid of chlorohydrogen 1 M or sodium of hydroxide solution 1M, water for injections
Transparent colourless liquid
of Psikhoanaleptiki. Psychostimulants and nootropa others. Tsitikolin
ATH N06BX06 Code
Tsitikolin Pharmacokinetics Absorption properties is well absorbed, bioavailability after intravenous administration and intake approximately identical.
Drug is metabolized in intestines and in a liver with formation of sincaline and cytidine. After reception concentration of sincaline in plasma significantly raise.
Tsitikolin is substantially distributed in structures of a brain, with rapid implementation of fractions of sincaline in structural phospholipids and fractions of cytidine – in cytidine nucleotides and nucleic acids. Tsitikolin gets into a brain and is actively built in cellular, cytoplasmic and mitochondrial membranes, forming a part of fraction of structural phospholipids.
Only 15% of the entered dose of a tsitikolin are brought out of a human body: less than 3% – kidneys and through intestines and about 12% with the exhaled CO2 (carbon dioxide).
In excretion of a tsitikolin with urine it is possible to allocate 2 phases: the first phase lasting about 36 hours during which clearance rate decreases and the second phase during which the speed of excretion decreases much more slowly. The same is observed with the exhaled CO2 – clearance rate quickly decreases approximately in 15 hours, and then decreases much more slowly.
Nootropic drug. Improves transfer of nervous impulses in cholinergic neurons, positively influences plasticity of neuronalny membranes and function of receptors. Improves a cerebral blood stream, strengthens metabolic processes in a brain, activates structures of a reticular formation of a brain and restores consciousness in a traumatic brain damage.
Цераксон® is a sincaline source, increasing synthesis of acetylcholine, and stimulates biosynthesis of structural (basic) phospholipids in a membrane of neurons that promotes improvement of function of membrane mechanisms, including, to functioning of ion-exchange pumps and the receptors shipped in them which modulation is a necessary condition of neurotransfer.
Цераксон® softens the symptoms which are observed in a hypoxia and ischemia of a brain, including a memory impairment, emotional lability, a bezinitsiativnost, difficulties during the performing of daily actions and self-service.
Цераксон® it is effective in treatment of cognitive, sensitive and motive neurologic disorders of a degenerative and vascular etiology.
– an acute period of a stroke
– the recovery period of an ischemic and hemorrhagic stroke
– a craniocereberal injury, the acute and recovery period
– the cognitive, sensitive and motive neurologic disorders caused by degenerative changes and vascular disorders of a brain
the Route of administration and doses
Intravenously appoint in the form of a slow intravenous injection (within 5 minutes) or drop intravenous injection (40-60 drops a minute).
During an acute period of a stroke and craniocereberal injury treatment there begin with intravenous administration of drug in a dosage 1000 – 2000 mg, daily, depending on disease severity within two weeks with the subsequent transition to intramuscular introduction 1-2 injections (500 – 2000 mg) a day or intake by a course up to 45 – 90 days. The dose and a course of administration of drug can be changed according to the recommendation of the attending physician.
Very seldom (& lt, 1/10000)
– allergic reactions, a small tortoiseshell, a dieback, erubescence up to purple coloring, a skin itching, hypostases, development of an acute anaphylaxis
– a headache, dizziness, hallucinations, excitement, insomnia, temperature increase, feeling of heat, a tremor
– nausea, vomiting, diarrhea
– increase or short-term lowering of arterial pressure
of the Contraindication
– hypersensitivity to drug components is possible
– a state with a high tone of parasympathetic nervous system (vagotonia)
Tsitikolin enhances effects of L-dihydroxyphenylalanin.
It is not necessary to appoint along with the medicines containing meklofeksonat.
in case of intracraneal hemorrhage it is impossible to exceed a daily dose of 1000 mg which needs to be entered intravenously slowly with a speed of 30 thaws a minute.
Solution in an ampoule is intended for single use. It has to be immediately used after opening of an ampoule.
Drug is compatible to all types of intravenous isotonic solutions and solutions of a dextrose.
Use in pediatrics
In children’s practice medicine is appointed if the expected therapeutic advantage exceeds possible risk.
Pregnancy and the period of a lactation
Though proofs of risk at use of drug during pregnancy or in the period of a lactation were not received, drug is appointed if the expected advantage exceeds potential risk for a fruit and the child.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous Tsitikolin mechanisms does not influence ability to control of vehicles and dangerous mechanisms.
Symptoms: strengthening of side effects of drug.
Long purpose of Tseraksona® was not followed by toxic effects regardless of a method of administration.
A form of release and packing
On 4 ml in glass ampoules of neutral glass with a protective plastic tube and a strip for a break of ampoules.
On 5 ampoules place in plastic blister strip packaging.
On 1 or 2 planimetric packs together with the instruction for medical use in the state and Russian languages place in a folding cardboard box.
To Store storage conditions at a temperature from 15ºC to 30ºC.
To store out of children’s reach!
not to apply a period of storage after the expiration date specified on packing.
According to the prescription
the Producer Ferrer Internasyonal, S.A., Barcelona, Spain.
Owner of the registration certificate
Ferrer Internasyonal, S.A., Spain.
The address of the organization accepting claims from consumers on quality of products (goods) in the territory of the Republic of Kazakhstan:
Representation Takeda Osteuropa Holding GmbH (Austria) in
Kazakhstan Almaty, Begalin St. 136 and
Phone number (727) 2444004
Fax number (727) 2444005
E-mail address of DSO-KZ@takeda.com